Latest Conference Coverage

The vice president of cell & gene therapy product development and the vice president of genetic medicine platforms at Pacira discussed the company’s symposium at ASGCT 2025.

The vice president of cell & gene therapy product development at Pacira BioSciences discussed findings related to the immunogenicity of the therapy’s high-capacity adenovirus vector.

The 3 FDA-approved CAR T-cell therapies showed comparable survival outcomes in DLBCL over a 3-year period.

Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute, discussed preclinical work on using dimerizing agent-regulated immune-receptor complex T-cells to target plasma cells.

Brian Kim, MBA, the chief executive officer of Mission Bio, also discussed the company’s plans for collaboration.

The patients also showed cessation of severe hypoglycemia events and hit recommended glycemic control targets.

Brian Kim, MBA, the chief executive officer of Mission Bio, discussed the company’s single cell assay platform in the context of the broader developing field cell and gene therapy field.

The hematologist at the Hematology and Stem Cell Transplants Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome discussed a study on the effect of comorbidities in patients receiving CAR-T.

Beam Therapeutics’ team provided insight on data the company presented at EHA's 2025 Congress.

The head of the clinical development program at Galapagos discussed the company's data presented at EHA's 2025 Congress.

The associate professor and the lymphoma stream lead at St Vincent’s Hospital, discussed data from a phase 1b trial for the CD19/CD20–directed bispecific CAR-T.

Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine, discussed safety and efficacy data from a phase 1 trial for Kite's CD19/CD20-directed CAR-T.

The associate professor of medicine at Stanford University School of Medicine discussed safety and efficacy data from a study presented at EHA's 2025 congress.

The overall response rate for the 11 treated patients was 72.7% at 3 months posttreatment.

The study included 3 boys and 6 girls who were treated with gene therapy for TDT at 5 to 16 years of age.

The data, from a study of 15 patients, were presented at EHA’s 2025 Congress.

The internal medicine resident at SUNY Upstate Medical University Hospital discussed the implications of findings from a deidentified database of EMR data.

The principal scientist at Bristol Myers Squibb discussed a biomarker analysis she presented at ASCO's 2025 meeting.

The hematologist/oncologist at the Cleveland Clinic discussed next steps after early promising results were presented at ASCO’s 2025 meeting.

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the implications of a large scale analysis of liso-cel recipients.

The associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado discussed the implications of a large scale analysis of liso-cel recipients.

The MSKCC Amyloidosis Program director and NEXICART-2 principal study investigator discussed results she presented at ASCO's 2025 meeting.

The hematologist/oncologist at the Cleveland Clinic discussed early results from a clinical trial evaluating the BCMA-directed CAR-T therapy.

The analysis included 153 patients with a median follow-up of 57.8 months.

Following treatment with NXC-201, all 7 patients (100%) showed normalized pathological disease markers.

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology discussed the broader implications of a positive data readout from a trial for the company’s autologous dendritic cell immunotherapy.

Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center, discussed her presentation at ASCO this year.

The associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado discussed an analysis of more than 1,500 patients treated with liso-cel across clinical trials and the real world.